sinovac biotech ltd chinese 科兴控股生物技术有限公司 chinese biopharmaceutical company based haidian district beijing focuses research development manufacture commercialization vaccines protect human infectious diseases company listed nasdaq exchange halted sinovacs trading february due proxy company faced bribery probes sinovacs commercialized vaccines include coronavac vaccine inlive enterovirus vaccine anflu influenza vaccine healive hepatitis vaccine varicella vaccine mumps coronavac inactivated virus vaccine developed phase iii clinical trials relies traditional technology similar sinopharm bibp vaccine covaxin otherwise known inactivatedvirus vaccines phase iii coronavac need frozen vaccine raw material formulating new doses could transported refrigerated temperatures flu vaccines realworld study ten millions chileans received coronavac found effective symptomatic hospitalization icu admissions brazil population serrana são paulo received coronavac preliminary results show deaths fell hospitalizations symptomatic cases indonesia real world data healthcare workers showed protection symptomatic infection vaccine beating results clinical phase iii results turkey published lancet showed efficacy based participants phase iii results brazil previously showed efficacy preventing symptomatic infections effective preventing mild cases needing treatment efficacy symptomatic infections increased interval days coronavac used vaccination campaigns various countries south north april sinovac production capacity two billion doses delivered million total currently manufactured several facilities june world health organization validated vaccine emergency sinovac signed purchase agreements million doses httpsenwikipediaorgwikisinovacbiotech